Fatigue News and Research

RSS

Some patients with Parkinson's experience sleep benefit

Some Parkinson's patients report that their motor function is better upon awakening in the morning, which is contrary to what would be expected after a night without medication. This phenomenon, known as sleep benefit, has been studied but no consistent variables have been found and in the last decade there has been little new research.

21 Jun 2012

Sufficient cancer pain relief may mean frequent follow up

US study findings show that just over half of cancer patients receiving outpatient palliative care who have mild or moderate pain intensity at initial consultation, report an increase to moderate or severe pain intensity by first follow up.

20 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

CAMFT offers five simple mental wellness tips to help manage stress

While managing stress can seem like an impossible goal, the California Association of Marriage and Family Therapists (CAMFT) reminds fathers to keep their mental wellness top of mind and seek help before stress leads to a larger issue, such as depression.

18 Jun 2012

Promising results from single iron dose study for fatigue treatment in iron deficient women

Dr Micheal Hedenus of the Haematology Unit of the Sundsval Hospital in Sweden will present promising results on a study on a single iron dose for fatigue treatment in iron deficient women at the 17th Congress of the European Hematology Association in Amsterdam.

From CSL Ltd 16 Jun 2012

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).

16 Jun 2012

Study finds no evidence to support an effect of THC on MS progression

The first large non-commercial study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS) shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

16 Jun 2012

IBMT linked with positive structural changes in brain connectivity

A Texas Tech University scientist studying the Chinese mindfulness meditation known as integrative body-mind training (IBMT) said he and other researchers have confirmed and expanded on changes in structural efficiency of white matter in the brain that can be related to positive behavioral changes in subjects practicing the technique for a month and a minimum of 11 hours total.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Depression, obesity two main culprits of excessive daytime sleepiness

Wake up, America, and lose some weight - it's keeping you tired and prone to accidents. Three studies being presented today at sleep 2012 conclude that obesity and depression are the two main culprits making us excessively sleepy while awake.

13 Jun 2012

Individuals on statins more likely to experience fatigue with exertion

In a study of more than 1,000 adults, researchers at the University of California, San Diego, found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both. The researchers suggest that these findings should be taken into account by doctors when weighing risk versus benefit in prescribing statins.

12 Jun 2012

Ethnic minority women ill-informed about heart disease

Black and Hispanic women are less likely than White women to be aware of heart disease risk and the symptoms of a heart attack, researchers say.

11 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Study suggests link between fungi and ulcerative colitis

Cedars-Sinai researchers say their examination of the fungi in the intestines suggests an important link between these microbes and inflammatory diseases such as ulcerative colitis.

7 Jun 2012

Vitamin D deficiency may be an important risk factor for erectile dysfunction

A paper just published hypothesizes that vitamin D deficiency may be an important risk factor for erectile dysfunction (ED).

7 Jun 2012

Iron and micronutrient-enriched foodstuffs can fight against anaemia

Iron deficiency and the anaemia it can cause are a major public health problem, affecting 2 billion people worldwide: mostly young children and pregnant women in developing countries. Despite decades of research into prevention and treatment, the situation is not improving, and is even deteriorating in some countries. Africa and India have the highest levels of anaemia, with more than 50% of women affected. In India, the illness is thought to cause up to 40% of maternal deaths.

6 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Lilly announces final results from ALIMTA Phase III study on NSCLC

Final results from PARAMOUNT, a Phase III study of ALIMTA (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company.

5 Jun 2012